From Delayed Recognition to Earlier Diagnosis: Two Pediatric Cases of Gaucher Disease

Background: Gaucher disease (GD) is an autosomal recessive inherited metabolic disorder characterized by the accumulation of glucosylceramide and related compounds within lysosomes. It commonly affects the visceral organs, bone marrow, and bones, with a highly variable clinical presentation and age of onset. Splenomegaly is the most common presenting sign and may occur with hepatomegaly and pancytopenia. This broad and variable presentation may complicate the recognition of GD, particularly in children presenting with prominent reticuloendothelial and hematologic manifestations.

Case 1 Presentation Summary: A 15-month-old boy was initially diagnosed with visceral leishmaniasis based on positive Leishmania testing, including a positive rK39 rapid test and Leishmania IgG, and treated with liposomal amphotericin B. Despite initial clinical improvement, marked hepatosplenomegaly and thrombocytopenia persisted. Serial ultrasound demonstrated progressive splenomegaly, increasing from 12.8 × 5.3 cm to 13.8 × 6.4 cm. Following two courses of amphotericin B and glucocorticoid therapy, splenomegaly and hypersplenism persisted, prompting splenectomy. Initial splenic histopathological evaluation suggested Langerhans cell histiocytosis. However, the subsequent recognition of a right femoral fracture and oculomotor apraxia prompted further diagnostic reassessment. Repeat histopathology, followed by genetic consultation targeted metabolic testing established a diagnosis of GD. Biochemical analysis revealed markedly reduced β-glucocerebrosidase activity (0.65 μmol/L/h) and elevated glucosylsphingosine (785.76 ng/mL). Genetic sequencing identified a homozygous pathogenic GBA variant, c.1448T>C (p.Leu483Pro), confirming GD Type 3.

Case 2 Presentation Summary: A 4-year-old boy presented with weakness, abdominal distension, and marked hepatosplenomegaly in the setting of pneumonia and confirmed Epstein-Barr virus (EBV) infection. The spleen was palpable 10 cm below the costal margin. Ultrasound demonstrated hepatomegaly (right lobe 11.7 cm) and splenomegaly (17.6 × 7.1 cm). Hematological assessment showed anemia (Hb 103 g/L), thrombocytopenia (72 × 10⁹/L), and leukopenia (4.40 × 10⁹/L). Although the patient was discharged following evaluation of the EBV infection, hepatosplenomegaly and pancytopenia persisted. Given the diagnostic experience from Case 1, Gaucher disease was considered earlier and targeted metabolic testing was performed. β-glucocerebrosidase activity was markedly reduced (0.07 μmol/L/h) and elevated glucosylsphingosine (453․22 ng/mL). GBA sequencing identified two heterozygous variants, c.754T>A (p.Phe252Ile) and c.1174C>T (p.Arg392Trp), confirming GD Type1.

Following definitive diagnosis, both patients were initiated on enzyme replacement therapy with imiglucerase.

Learning Points & Discussion: These cases underscore the importance of maintaining a broad differential diagnosis, particularly when a patient’s clinical course diverges from the expected trajectory. Persistent or progressive hepatosplenomegaly accompanied by hematologic abnormalities should prompt comprehensive diagnostic reassessment. Although rare metabolic and lysosomal storage disorders such as Gaucher disease may be overlooked during initial evaluation, clinicians should remain alert to these conditions when the clinical presentation is not fully explained by the initial diagnosis. The diagnostic experience from the first case facilitated earlier consideration and diagnosis in the second, highlighting the importance of avoiding premature diagnostic closure.